

# ANTIANGINAL DRUGS

## LEARNING OUTCOMES

Recognize variables contributing to a balanced myocardial supply versus demand



Expand on the drugs used to alleviate acute anginal attacks versus those meant for prophylaxis & improvement of survival

Detail the pharmacology of nitrates, other vasodilators, and other drugs used as antianginal therapy



# WHAT IS ANGINA PECTORIS?

A Pain is caused either by obstruction (severity) due to ischemia of heart muscle



Typical distribution of referred pain



© Original Artist  
Reproduction rights obtainable from  
[www.CartoonStock.com](http://www.CartoonStock.com)

due to (accumulation of metabolites secondary to




"You say it's a sharp, stabbing pain. Hmmm ... sharp ... stabbing pain."

search ID: jmp0070420

# WHAT IS BASIC MECHANISM OF ANGINA PECTORIS?


## WHAT ARE THE DETERMINANTS OF OXYGEN DEMAND AND SUPPLY?



**Coronary Perfusion Pressure = Aortic Pressure - Left Ventricular End diastolic Pressure**

MYOCARDIAL OXYGEN DEMAND IS DETERMINED BY:-


MYOCARDIAL OXYGEN DEMAND IS DIMINISHED BY:-



**Reducing contractility**  
**Reducing heart rate**  
**Reducing the preload**  
**Reducing the afterload**

**MYOCARDIAL OXYGEN SUPPLY IS DETERMINED BY:-**

**MYOCARDIAL OXYGEN SUPPLY IS ENHANCED BY:-**



Reducing coronary vascular resistance  
Prolonging diastolic period  
Reducing external compression  
Dilating collateral vessels  
Optimizing hemoglobin & RBCs

# Types of Angina Pectoris

## Stable Angina

**Effort ,  
Typical.**

Atherosclerosis.

**Exercise,  
Emotion,  
Heavy meal.**

**Pain**

## Variant Angina

**Prinzmetal.**

**$\alpha$ - receptor  
mediated V.C.**

With or without  
atherosclerosis.

**Pain even at rest**

## Unstable Angina

**Accelerated.**

**Severe type.**

change in pattern.

↑ frequency & or  
duration of pain.

# TREATMENT OF ANGINA PECTORIS

## 1-Agents that improve symptoms & ischemia

Traditional Approach

## New approaches

Metabolic  
modulation  
(Trimetazidine)

K<sup>+</sup> channel opener  
(Nicorandil)

Sinus node  
inhibition  
(Ivabradine)

Late Na<sup>+</sup>  
current  
inhibition  
(Ranolazine)

# TREATMENT OF ANGINA PECTORIS

## 2-Agents that improve prognosis

 Aspirin / Other antiplatelets

 Statins

 ACE Inhibitors

  $\beta$ -AD blockers



# ORGANIC NITRATES

## MECHANISM OF ACTION

LONG ACTING

ISOSORBIDE MONONITRATE

SHORT ACTING

NITROGLYCERIN

Sodium Nitrate

Organic Nitrates





Nitric  
vasc

ate  
ell t

cGM. activates cGMP to produce relaxation

# HEMODYNAMIC EFFECTS OF NITRATES

Shunting of flow from normal area to ischemic area by dilating collateral vessels



# PHARMACOKINETICS

## Oral isosorbide dinitrate & mononitrate


Very well absorbed . Mononitrate, 100% bioavailability  
the liver (10-20%) bioavailability

The dinitrate undergoes denitration to two  
mononitrates → both possess antianginal activity

entral

( $t_{1/2}$  1-3 hours)

Further denitrated metabolites conjugate to glucuronic acid  
in liver. Excreted in urine.



# INDICATIONS

**IN STABLE ANGINA;**

**IN VARIANT ANGINA** → **sublingual GTN**

**Prevention; Persistent prophylaxis** → **Isosorbide mono or dinitrate**

**Heart Failure**

**Refractory AHF** → **IV GTN**

**CHF** → **Isosorbide mononitrate + hydralazine**  
*[ if contraindication to ACE Is]*

**AMI** → **IV GTN**

# CONTRAINDICATIONS

Concomitant administration of PDE<sub>5</sub> Inhibitors

Known sensitive to organic nitrates

Sexual stimulation

Organic nitrates

Glaucoma; nitrates → ↑ aqueous humor formation

Nitric oxide formation

Sildenafil

Activates

Headache, cerebral haemorrhage, hypotension

GTP

cGMP

GMP

Guanylate cyclase

PDE


Uncorrected hypovolemia

Corpus cavernosum smooth muscle relaxation

Vascular smooth muscle relaxation

Erection

Vasodilation



Sildenafil + nitrates → Severe hypotension & death

# ADVERSE DRUG REACTIONS

THROBING HEADACHE



FLUSHING IN BLUSH AREA



TACHYCARDIA & PALPITATION



POSTURAL HYPOTENSION, DIZZINESS & SYNCOPE





RARELY METHEMOGLOBINEMIA

# PREPARATIONS


## Nitroglycerin

### Sublingual t

### Transderma

**Key:**  Onset of action  
 Duration of action

### *Nitroglycerin*




Oral or bucal sustained release  
I.V. Preparations

# PREPARATIONS

## Isosorbide dinitrate

- Dinitrate Sublingual tablets
- Dinitrate Oral sustained release
- Infusion Preparations



▪ Mononitrate O



## NITRATES TOLERANCE

Loss of vasodilator response of nitrates on use of long-acting preparations (oral, transdermal) or continuous intravenous infusions, for more than a few hours without interruption.

### MECHANISM

1-Compensatory neurohormonal counter-regulation

2-Depletion of free-SH groups

**Nitrate tolerance can be overcome by:**

**Smaller doses at increasing intervals (Nitrate free periods twice a day).**

**Giving drugs that maintain tissue SH group e.g. Captopril.**

# Calcium channel blockers

Classification

1-Chemical structure

2-Selectivity

Dihydropyridines:-

Nifedipine, Nisoldipine, Amlodipine

Nifedipine ,

Vascular smooth muscle

Verapamil  
Phenylalkylamines:-


Cardiomyocytes

Diltiazem  
Benzothiazines:-

Intermediate

# Mechanism of Action

Binding of calcium channel blockers [CCBs] to the L-type Ca channels ↓ their frequency of opening



## Antianginal Action

↓ **Cardiomyocyte Contraction** → ↓ cardiac work through their –ve inotropic & chronotropic action (verapamil & diltiazem) → **↓ myocardial oxygen demand**

↓ **VSMC Contraction** → ↓ After load → ↓ cardiac work → **↓ myocardial oxygen demand**

Coronary dilatation → **↑ myocardial oxygen supply**

## Therapeutic Uses

### IN VARIANT ANGINA

Short acting dihydropyridine should be avoided ??

▶ Attacks prevented (> 60%) /  
sometimes variably aborted

Can be combined to  $\beta$ -AR blockers???

### IN UNSTABLE ANGINA

Can be combined with nitrates???

Seldom added in refractory cases

Dihydropyridenes useful antianginal if with CHF??

# Beta Adrenoceptor Blockers

Examples Atenolol, Bisoprolol, Metoprolol ( $\beta_1$  - Selective )

## Antianginal Mechanism

### B-Blockers

Decrease heart rate & Contractility

Increase duration of diastole

Increase coronary blood flow

Increase oxygen supply

Decrease workload

Decrease O<sub>2</sub> consumption

# Beta Adrenoceptor Blockers

**Indications in angina**

**In stable angina**

**Regular prophylaxis, selective are preferred?**

**First choice for chronic use?**

**Can be combined with nitrates?**

**Can be combined with dihydropyridine CCB?**

**Verapamil?**

**In variant angina**

**Contraindicated?**



# Beta Adrenoceptor Blockers

**Indications in angina**

**In Unstable angina**

**Halts progression to MI, improve survival**

**In Myocardial infarction**

**Reduce infarct size**

**Reduce morbidity & mortality**

→ reduce **O<sub>2</sub> demand**

→ reduce **arrhythmias**

# Beta Adrenoceptor Blockers

$\beta$ - blockers should be withdrawn gradually?

Given to diabetics with ischemic heart disease?


# Potassium channel openers

**Nicorandil**

**Mechanism**

Activation of ATP-sensitive K<sup>+</sup> channels

- Dilation of coronary resistance arterioles




Nitrate-associated effects

- Vasodilation of coronary epicardial arteries

It has dual mechanism of action;

1. Opens K<sub>ATP</sub> channels (> arteriolar dilator)
2. NO donor as it has a nitrate moiety (> venular dilator)



# Pharmacodynamic Effects

**As K channel opener**

**As nitric oxide donor**

→ opening of K channels

→ hyperpolarization → vasodilatation

**NO ↑ cGMP/PKG → vasodilatation**

On cardiomyocytes opening of K channels → repolarization

→ ↓ cardiac work

## **Indications**

**Prophylactic 2nd line therapy in stable angina & refractory variant angina**

## **ADRs**

**Flushing, headache,  
Hypotension, palpitation, weakness  
Mouth & peri-anal ulcers, nausea and vomiting.**


# Metabolically Acting Agents

e.g. Trimetazidine

O<sub>2</sub> requirement of glucose pathway is low

During rise,

levels  
way



Reduces O<sub>2</sub> demand without altering hemodynamics

# Trimetazidine

Indications

Used as an add on therapy

ADRs

GIT disturbances

Contraindications

Hypersensitivity reaction

Pregnancy & lactation

# Ranolazine


Inhibits the late sodium current which increases during ischemia

It prolongs  
Class Ia & II

Toxicity develops with  
inhibitors as  
*antibiotics, (*

ADRs:- dizziness

Used in chronic



n;

0

*macrolide*

r drugs



# Ivabradine

Ivabradine Selectively blocks  $I_f$



Ivabradine reduces slope of depolarization, slowing HR, reducing myocardial work &  $O_2$  demand

## Ivabradine

Used in treatment of chronic stable angina in patients with normal sinus rhythm who do not take  $\beta$ -blockers



ADR:- luminous phenomena



$I_f$  current is activated at -60 mV

## Agents that improve prognosis

- Aspirin / other antiplatelet agents
- ACE inhibitors
- Statins
- $\beta$  - blockers

**Halt progression**  
**Prevent acute insult**  
**Improve survival**

# New indication for an old drug

An average cost of developing a new drug is 2.6 billion dollars

It takes at least ten years for a drug to be developed

Computer-aided screening for existing drug activity is applied

The computer model will predict whether a given molecule will bind to a target and if so how strongly

Professor Didier Roult, infectious disease institute in Marseille, France

Hydroxy chloroquine can stop the virus from being contagious in just 6 days